Asset Details
Do you wish to reserve the book?
HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies
Do you wish to request the book?
HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies
2020
Overview
Purpose
Targeted therapies have resulted in major advances in the treatment of HER2-positive breast cancers. Despite this, up to 70% of patients will develop resistance to treatment within 2 years and new strategies for targeting resistant disease are needed.
Methods
To identify potential resistance mechanisms, we used the mouse MMTV-NIC-PTEN
+/−
spontaneous model of HER2-positive breast cancer and the pan-HER family kinase inhibitor sapatinib. Vehicle and sapatinib-treated tumors were evaluated by immunohistochemistry and proteomic analysis. In vitro studies were carried out to define the role of heme oxygenase 1 (HO-1) and autophagy in resistance to sapatinib and lapatinib, another pan-HER family kinase inhibitor.
Results
Treatment of tumor-bearing MMTV-NIC-PTEN
+/−
mice with sapatinib resulted in delayed tumor progression and increased survival. However, tumors eventually progressed on treatment. Proteomic analysis identified proteins associated with cellular iron homeostasis as being upregulated in the sapatinib-treated tumors. This included HO-1 whose overexpression was confirmed by immunohistochemistry. Overexpression of HO-1 in HER2-expressing SKBR3 breast cancer cells resulted in reduced sensitivity to both pan-HER family kinase inhibitors sapatinib and lapatinib. This was associated with increased autophagy in the HO-1 over-expressing cells. Furthermore, increased autophagy was also seen in the sapatinib-treated tumors. Treatment with autophagy inhibitors was able to increase the sensitivity of the HO-1 over-expressing cells to both lapatinib and sapatinib.
Conclusion
Together these data indicate a role for HO-1-induced autophagy in resistance to pan-HER family kinase inhibitors.
Publisher
Springer US,Springer,Springer Nature B.V
Subject
/ Animals
/ Antineoplastic Agents - pharmacology
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - pathology
/ Drug Evaluation, Preclinical
/ Female
/ Heme
/ Heme Oxygenase-1 - metabolism
/ Humans
/ Kinases
/ Medicine
/ Membrane Proteins - metabolism
/ Mice
/ Oncology
/ Protein Kinase Inhibitors - pharmacology
/ Proteins
/ Receptor, ErbB-2 - antagonists & inhibitors
/ Receptor, ErbB-2 - metabolism
/ Tumors
